Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

Jahr

2018

Autoren

Albrecht P, Bjørnå IK, Brassat D, Farrell R, Feys P, Hobart J, Hupperts R, Linnebank M, Magdič J, Oreja-Guevara C, Pozzilli C, Salgado AV, Ziemssen T.

Verlag

Ther Adv Neurol Disord. 2018 Oct 5;11:1756286418803248.

Link

https://doi.org/10.1177/1756286418803248

Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting

RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis

Challenges and implications of anti-JCV antibody serology variability among different assays in natalizumab treatment: A call for standardization and transparency in clinical practice

MS brain health quality standards: a survey on the reality in clinical practice in Germany

Best supportive care for patients with primary progressive multiple sclerosis (PPMS) in Germany prior to ocrelizumab treatment: Final results from the RETRO PPMS study

Harmonized Data Quality Indicators Maintain Data Quality in Long-Term Safety Studies Using Multiple Sclerosis Registries/Data Sources: Experience from the CLARION Study